Targeting the complement system in systemic lupus erythematosus and other diseases

Copyright © 2013. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 148(2013), 3 vom: 30. Sept., Seite 313-21
Auteur principal: Barilla-Labarca, Maria-Louise (Auteur)
Autres auteurs: Toder, Kiley, Furie, Richard
Format: Article en ligne
Langue:English
Publié: 2013
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Review Complement Complement inhibitors Eculizumab Lupus nephritis Systemic lupus erythematosus Treatment Complement Inactivating Agents Complement System Proteins 9007-36-7
Description
Résumé:Copyright © 2013. Published by Elsevier Inc.
The importance of the complement system in the pathogenesis of systemic lupus erythematosus (SLE) has long been recognized. However, despite an unprecedented amount of SLE clinical trial activities ongoing at this time, complement inhibitors have been omitted from the therapeutic assault on this disease. We review data generated from murine lupus that provide scientific support for the study of human SLE. Also reviewed is the sole study of a complement inhibitor, eculizumab, performed in patients with SLE. We conclude with a review of other inflammatory diseases where ongoing programs might provide the groundwork for the development of complement inhibitors in SLE
Description:Date Completed 23.10.2013
Date Revised 07.08.2013
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2013.02.014